Clinical Trials Browser

nimotuzumab × Head & Neck × 1 year × Clear all

NCT07601737 2026-05-22

Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07535567 2026-04-30

NimoBenSeq

Phase 2/3 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07445048 2026-04-17

Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07354984 2026-01-21

PIONEER-HN

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07353723 2026-01-20

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

Phase 2 Recruiting

Pathologic Complete Response, Head and Neck Neoplasms

NCT07333274 2026-01-12

Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06509009 2025-09-19

Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT07070479 2025-09-18

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

Phase 2 Recruiting

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence